|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The presence of R273H-P53 conferred the cancer cells with drug resistance not only against the widely used chemotherapeutic agents like cisplatin (CDDP) or 5-flurouracil (5-FU) but also against potent alternative modes of therapy like proteasomal inhibition.
|
30723502 |
2019 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
These results indicate that mutant TP53 G245C and R273H can lead to more aggressive phenotypes and enhance cancer cell malignancy, which further uncover TP53 function in carcinogenesis and might be useful in clinical diagnosis and therapy of TP53 mutant cancers.
|
30126368 |
2018 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Expression of mutp53-R273H also makes cancer cells more sensitive to DNA2 depletion or DNA2 inhibitors.
|
28439015 |
2017 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
R273H mutation of p53 has been closely implicated in human cancer.
|
26898459 |
2016 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Targeting CD24 provides a strategy to enhance mutant p53-restoring therapies, especially in patients with TP53(R273H) prostate cancer.Clin Cancer Res; 22(10); 2545-54.©2015 AACR.
|
26712693 |
2016 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
These findings open the possibility that blocking of PI3K/AKT will have therapeutic benefit in mutant p53-R273H expressing cancers.
|
26181206 |
2015 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancy.
|
24677579 |
2014 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
These activities are attributable to mutant p53(R273H) gain of function and might underlie its well-documented oncogenic nature in human cancer.
|
22899716 |
2012 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Many p53 cancer mutants, including the hot spot mutations (R175H, R248W and R273H), not only lose p53-dependent tumor-suppressor activities, but also acquire new oncogenic activities to promote cancer.
|
19881536 |
2010 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
R273H expression in p53-null cancer cell SK-OV-3 and Saos-2 did not significantly affect cell invasion and migration activities.
|
17636407 |
2007 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
To elucidate the nature of the gain of function, we introduced the most common p53 cancer mutations (R248W and R273H) independently into the humanized p53 knock-in (HUPKI) allele in mice.
|
17417627 |
2007 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Neither dicoumarol nor curcumin dissociated the complexes of NQO1 and the human cancer hot-spot p53 R273H mutant and therefore did not induce degradation of this mutant.
|
15809436 |
2005 |
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results show: (1) wild-type p53 stimulates the transcription of reporter genes with p53CON and RGC in their 5' region while most p53 mutants occurring in human cancers have lost this activity; (2) the R273H mutant retains transcriptional activity for the p53CON sequence but not RGC; (3) some mutants are temperature-sensitive for the transcriptional activity with the p53CON but not the RGC sequence; (4) p53 mutants vary in their ability to inhibit wild-type p53 transactivation but there is no difference between p53CON and RGC sequences; (5) lung cancer cells with endogenous mutant p53 proteins (M246I in H23 cells and R248L in H322 cells) retain transcriptional activity for the p53CON but not the RGC sequence.
|
8336941 |
1993 |